Weight loss can be a challenge, even for those who eat healthily and exercise regularly. But injectable type 2 diabetes ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...

They are expected to act as a catalyst in medicine, society, the economy, and even in... fuel consumption - The astounding ...

With Eisai and Biogen’s Leqembi and Eli Lilly’s Kisunla launching onto the market, the 2024 Clinical Trials of Alzheimer’s ...

Conditions are getting a bit more challenging for the drugmaker.

In good news for those averse to injections, GLP-1 agonist medication is a step closer to being offered in oral pill form, ...

A small player like Viking may also win by attracting a partner or even a company that will offer to acquire the biotech.

Currently, two innovators are dominating the $50 billion market : Novo Nordisk’s Ozempic or Wegovy (Semaglutide) and Eli ...

The FDA removed Wegovy, Ozempic, Mounjaro, and Zepbound from its drug shortage list for the first time in two years. The move ...

AstraZeneca and Viking Therapeutics both presented encouraging data on their obesity pills. Meanwhile, here’s how Americans ...

Bullish option flow detected in Eli Lilly (LLY) with 44,692 calls trading, 3x expected, and implied vol increasing over 1 point to 29.25%. 11/8 weekly 820 calls and 11/8 weekly 830 calls are the most ...

Novo Nordisk reported earnings, posting some chunky year-over-year growth and far outperforming its only real rival at the ...